



# Coding-Complete Genome Sequence of SARS-CoV-2 Isolate from Bangladesh by Sanger Sequencing

M. Moniruzzaman,<sup>a</sup>  Mohammad Uzzal Hossain,<sup>b</sup> M. Nazrul Islam,<sup>c</sup> M. Hadisur Rahman,<sup>a</sup> Irfan Ahmed,<sup>a</sup> Tahia Anan Rahman,<sup>a</sup> Arittra Bhattacharjee,<sup>b,d</sup> M. Ruhul Amin,<sup>e</sup> Asif Rashed,<sup>f</sup> Chaman Ara Keya,<sup>d</sup> Keshob Chandra Das,<sup>a</sup>  M. Salimullah<sup>a</sup>

<sup>a</sup>Molecular Biotechnology Division, National Institute of Biotechnology, Dhaka, Bangladesh

<sup>b</sup>Bioinformatics Division, National Institute of Biotechnology, Savar, Dhaka, Bangladesh

<sup>c</sup>Plant Biotechnology Division, National Institute of Biotechnology, Savar, Dhaka, Bangladesh

<sup>d</sup>Department of Biochemistry and Microbiology, North South University, Bashundhara, Dhaka, Bangladesh

<sup>e</sup>Center for Medical Biotechnology, MIS, Directorate General of Health Services, Dhaka, Bangladesh

<sup>f</sup>Department of Microbiology, Mugda Medical College, Dhaka, Bangladesh

**ABSTRACT** A coding-complete genome sequence of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolate was revealed. The sample for the virus was isolated from a female patient from Dhaka, Bangladesh, suffering from coronavirus disease-2019 (COVID-19).

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the *Coronaviridae* family and *Betacoronavirus* genus, is the causative agent of pandemic coronavirus disease-2019 (COVID-19). In Bangladesh, the rate of positive cases and the death toll from COVID-19 are increasing at an alarming rate (<https://corona.gov.bd/>). To understand the genomic characteristics of SARS-CoV-2 in Bangladesh, several isolates have been sequenced and deposited in GISAID (<https://www.gisaid.org/>). However, those isolates have been sequenced using a next-generation sequencing platform, except for the one we are reporting. In this study, we sequenced the viral genome by Sanger sequencing technology, which is a gold standard method and is necessary for thorough genomic analysis (1).

The isolate (SARS-CoV-2/human/BGD/NIB\_01/2020) was collected from an oropharyngeal specimen on 11 May 2020. The patient was a 28-year-old saleswoman who tested positive (via reverse transcriptase PCR [RT-PCR]) for COVID-19 with symptoms of cough, mild fever, and throat congestion. (all applicable international, national, and/or institutional guidelines for the care and use of animals were followed; ethical approval number NIBREC2020-01). The viral RNA was extracted directly from the patient's specimen using the PureLink viral RNA/DNA minikit (Invitrogen). The viral RNA was then converted into cDNA using a SuperScript VILO cDNA synthesis kit (Invitrogen).

To cover the whole genome of the virus, 48 pairs of primers were designed by following two conditions: (i) their sequence is conserved among all the available SARS-CoV-2 isolates, and (ii) the terminal of the amplicons will overlap the adjacent amplicon (Table 1). These primers underwent PCR and generated 96 amplicons, which were visualized using 1.5% agarose gel electrophoresis. The PCR products were then purified using the PureLink PCR purification kit (Thermo Fisher Scientific, USA). These purified amplicons were finally sequenced with 2× coverage using the Sanger dideoxy method by "ABI 3500" with a BigDye Terminator version 3.1 cycle sequencing kit (Applied Biosystems, USA).

The raw reads were assembled using DNA Sequence Assembler version 4 (2013)

**Citation** Moniruzzaman M, Hossain MU, Islam MN, Rahman MH, Ahmed I, Rahman TA, Bhattacharjee A, Amin MR, Rashed A, Keya CA, Das KC, Salimullah M. 2020. Coding-complete genome sequence of SARS-CoV-2 isolate from Bangladesh by Sanger sequencing. *Microbiol Resour Announc* 9:e00626-20. <https://doi.org/10.1128/MRA.00626-20>.

**Editor** John J. Dennehy, Queens College

**Copyright** © 2020 Moniruzzaman et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to M. Salimullah, [salim2969@gmail.com](mailto:salim2969@gmail.com).

**Received** 29 May 2020

**Accepted** 19 June 2020

**Published** 9 July 2020

**TABLE 1** Information about primers, amplicon size, and overlapping length

Amplicon	Primer	Sequence	Product size (bp)	Overlapping length (bp)
1	Forward	AGGTTTATACCTTCCCAGG	765	131
1	Reverse	CACCACTGCTATGTTTAGTG		
2	Forward	CGCAAGGTTCTTCTTCGTA	797	100
2	Reverse	AGACTATGCTCAGGTCCTAC		
3	Forward	AAGAAGGTGCCACTACTTG	794	114
3	Reverse	GTTAGTTAGCCACTGCGAA		
4	Forward	ACTGAGACTCATTGATGCTA	788	130
4	Reverse	TCACACTCTTGTAACCTTGC		
5	Forward	AGAAAAGTACTGTGCCCTTG	783	131
5	Reverse	ACCACTGTTGGTTTTACCTT		
6	Forward	GATGGAACTTACACCAGTTG	781	110
6	Reverse	GTCATAACAAGAGTGGCAG		
7	Forward	GAAGAAGTTACAACAACCTCTGG	718	136
7	Reverse	AAACTGTAGCTGGCACTTTG		
8	Forward	TGTAGCGTCACTTATCAACA	746	158
8	Reverse	CAGTGGCAAGATAACAGTTG		
9	Forward	CTTACGTGTTGAGGCTTTT	720	130
9	Reverse	CATCCGTAATAGGACCTTTGT		
10	Forward	TTGTGCTAGTGAGTACACTG	760	150
10	Reverse	AATGTCTCCTACAACCTTCGG		
11	Forward	TGATGTACTGAAGTCAGAGG	737	90
11	Reverse	AATAGCCTTCTCTGTAACCAG		
12	Forward	TTCTTTAATCTACTCAACCGC	706	118
12	Reverse	CTGTAGTGACAAGTCTCTCG		
13	Forward	ATGCTAATGGAGGTAAGGC	701	115
13	Reverse	ACAACATATGCCAGTAACTTC		
14	Forward	CTTTTATTTACAGCAGCTCGG	714	133
14	Reverse	GTGCGTAATATCGTGCCA		
15	Forward	GCTGATTTTGACACATGGTT	812	196
15	Reverse	GGTAAGAATGAGTAACTGGTG		
16	Forward	CCTATTGGTGCTTTGGACATA	727	146
16	Reverse	AACCCTCAACTTTACCAGATG		
17	Forward	CTTGTTGCATCTCGCAAAG	767	112
17	Reverse	TCGATTGAGAAACCACCTGT		
18	Forward	TTGTTGACAGGCAAACAGC	770	121
18	Reverse	ACCATCATATACACAGTTCT		
19	Forward	TGACATGGTTGGATATGGTTG	794	172
19	Reverse	GTTTATGTCTACAGCACCTT		
20	Forward	AATTGTGGGCTCAATGTGT	787	155
20	Reverse	GCAACAGGACTAAGCTCATTA		
21	Forward	GGAAATCCAACAGGTTGTAGA	795	90
21	Reverse	ACAGGGTCATTAGCACAAAGT		
22	Forward	GTTGCCACATAGATCATCCAA	790	233
22	Reverse	AACAATACCAGCATTTCGC		
23	Forward	GCAGACCTCGTCTATGCTTT	813	147
23	Reverse	GCACGTAGTGCCTTATCT		
24	Forward	CCACTTCAGAGAGCTAGGTG	782	114
24	Reverse	GTGAGGGTTTTCTACATCACT		
25	Forward	ATTGAAATCAATAGCCGCCA	775	117
25	Reverse	ATCTGGGTAAGGAAGGTACA		
26	Forward	GTCTGAAGCAAATGTTGGA	805	142
26	Reverse	GAGTCTTTCAGTACAGGTGTT		
27	Forward	TGTGTGCTAATGGACAAGTT	784	132
27	Reverse	TCAAAACACTCTACACGAGC		
28	Forward	CTTCTGCTCGCATAGTGAT	769	191
28	Reverse	CAAGAGTGAGCTGTTTCAGT		
29	Forward	AATAGGCGTGGTAAGAGAAT	790	139
29	Reverse	GTACATAAGTGGTATGAGGTGT		
30	Forward	AGCTAGGTTTTTCTACAGGTG	756	152
30	Reverse	CTTTGTCACTACAAGGCTGT		
31	Forward	GTAGAAAGGTTCAACACATGG	733	144
31	Reverse	ATAGAACTGGTACTTCACCC		
32	Forward	GCTTTAGCTTGTGGGTTTAC	808	139
32	Reverse	CCACCTAACTGACTATGACT		

(Continued on next page)

TABLE 1 (Continued)


Amplicon	Primer	Sequence	Product size (bp)	Overlapping length (bp)
33	Forward	CAAGAATTTAAACCCAGGAG	758	155
33	Reverse	GCATCAGAGACAAAGTCATT		
34	Forward	CACATTAACATTAGCTGTACCC	781	182
34	Reverse	TGACTAGAGACTAGTGGCA		
35	Forward	AAGGGTACTGCTGTTATGT	775	116
35	Reverse	TTAATAGGCGTGTGCTTAGA		
36	Forward	TCAGCCTTTTCTTATGGACC	794	104
36	Reverse	TCCAAGCTATAACGCAGC		
37	Forward	TTAGAGGTGATGAAGTCAGA	760	149
37	Reverse	TGTTCAAGCCCTATTAACA		
38	Forward	TAACCAGTTGCTGTTCTTT	797	191
38	Reverse	CAATCATTTTCTGCTGAGCA		
39	Forward	CAGATCCATCAAACCAAGC	771	137
39	Reverse	GCAAGAAGACTACACCATGA		
40	Forward	TCAGAGCTTCTGCTAATCTTG	759	137
40	Reverse	GTAATTTGACTCCTTTGAGC		
41	Forward	TTGCCATAGTAATGGTGACA	798	120
41	Reverse	AGCTGGTAATAGTCTGAAGTG		
42	Forward	GCACAACAAGTCCTATTTCT	784	170
42	Reverse	CCATAACAGCCAGAGGAAAA		
43	Forward	GCAGATTCACGCTACT	707	117
43	Reverse	TAGTAACCTGAAAGTCAACG		
44	Forward	GCTACAGGATTGGCAACTAT	785	174
44	Reverse	TTTCATGTTTCGTTAGGCGT		
45	Forward	CACCTTGCTTCACTCAA	791	180
45	Reverse	TCTGGACTGCTATTGGTGT		
46	Forward	CAGATTCAACTGGCAGTAA	793	187
46	Reverse	TTTCCTGGGTTTGTCTGG		
47	Forward	CTGCTTGACAGATTGAACCA	698	242
47	Reverse	CTTGTGCTATGTAGTTACGAGA		
48	Forward	ATGAAACTCAAGCCTTACCG	518	
48	Reverse	CCTTTCGTGCAGGTCAATA		

(Heracle BioSoft) and verified with SeqMan Pro version 14.1 (DNASTar, Madison, WI). After assembly, 48 contigs with 94 overlapping regions were obtained. These overlapping regions were visualized using CLC Genomics Workbench version 20.0.4 and merged with EMBOSS: merger (2).

The assembled viral genome consists of a single-stranded positive (+) RNA that is 29,724 nucleotides long. The NCBI BLASTN program (3) showed that the genome was mostly similar to SARS-CoV-2/human/BGD/CHRF\_0001/2020 (GenBank accession number [MT476385.1](https://www.ncbi.nlm.nih.gov/nuclseq/MT476385.1)). From NCBI, the FASTA sequences of 7 mostly similar genomes from Bangladesh, India, Sri Lanka, and the United States were taken along with the reference genome. Another 16 genomes of SARS-CoV-2 that were isolated in Bangladesh were collected from GISAID (<https://www.gisaid.org/>). The genomes were aligned with MAFFT version 7 using default parameters (4). The phylogenetic tree was constructed using FastTree version 2.1.10 (5) through the Galaxy platform (6). Here, the tree was built by nucleotide alignment using the generalized time-reversible model (GTR) plus the CAT nucleotide evolution model (GTR+CAT). The tree was visualized using iTOL (7), where the tree structure was rerooted on the position of reference isolate SARS-CoV-2 Wuhan-Hu-1.

The genome has 8 nucleotide differences from the closest isolate. Interestingly, except for isolate SARS-CoV-2/human/BGD/CHRF0001/2020, the other strains of SARS-CoV-2 from Bangladesh showed separate clades and distant genetic relations. The tree also demonstrated that our viral genome and three isolates from the United States share an ancestor (Fig. 1).

**Data availability.** The complete nucleotide sequence of this SARS-CoV-2 isolate (SARS-CoV-2/human/BGD/NIB\_01/2020) has been deposited in GenBank under the accession number [MT509958](https://www.ncbi.nlm.nih.gov/nuclseq/MT509958).



**FIG 1** Phylogenetic analysis of the SARS-CoV-2/human/BGD/NIB\_01/2020 isolate. Nucleotide alignment and the GTR+CAT nucleotide evolution model was applied to construct the tree. The tree was visualized using i-TOL. Here, the x axis represents the tree scale. A scale bar with a 0.0001 value is given on the top. The genome (labeled in red) shares a common ancestor with some isolates from the United States.

**ACKNOWLEDGMENTS**

We are grateful to the Ministry of Science and Technology for its extensive support during this research work.

This study was funded by the National Institute of Biotechnology, Ministry of Science and Technology, government of the People’s Republic of Bangladesh.

**REFERENCES**

1. Besser J, Carleton HA, Gerner-Smidt P, Lindsey RL, Trees E. 2018. Next-generation sequencing technologies and their application to the study and control of bacterial infections. *Clin Microbiol Infect* 24:335–341. <https://doi.org/10.1016/j.cmi.2017.10.013>.
2. Rice P, Longden I, Bleasby A. 2000. EMBOSS: the European Molecular Biology Open Software Suite. *Trends Genet* 16:276–277. [https://doi.org/10.1016/S0168-9525\(00\)02024-2](https://doi.org/10.1016/S0168-9525(00)02024-2).
3. Zhang Z, Schwartz S, Wagner L, Miller W. 2000. A greedy algorithm for aligning DNA sequences. *J Comput Biol* 7:203–214. <https://doi.org/10.1089/10665270050081478>.
4. Kazutaka K, John R, Kazunori DY. 2019. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. *Brief Bioinform* 20:1160–1166. <https://doi.org/10.1093/bib/bbx108>.
5. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2: approximately maximum-likelihood trees for large alignments. *PLoS One* 5:e9490. <https://doi.org/10.1371/journal.pone.0009490>.
6. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, Chilton J, Clements D, Coraor N, Grünig BA, Guerler A, Hillman-Jackson J, Hiltmann S, Jalili V, Rasche H, Soranzo N, Goecks J, Taylor J, Nekrutenko A, Blankenberg D. 2018. The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. *Nucleic Acids Res* 46:W537–W544. <https://doi.org/10.1093/nar/gky379>.
7. Letunic I, Bork P. 2019. Interactive Tree of Life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res* 47:W256–W259. <https://doi.org/10.1093/nar/gkz239>.